[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336468-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336468-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","considerations-regarding-an-updated-meta-analysis-of-the-optimal-duration-of-oxaliplatin-based-adjuvant-chemotherapy","Considerations regarding an updated meta-analysis of the optimal duration ofoxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer","","Letter to the editor reviewing a recent meta-analysis on optimal duration of oxaliplatin-based adjuvant chemotherapy for stage II–III colon cancer. It discusses key recommendations favoring 6-month FOLFOX for high-risk stage III and 3-month CAPEOX for stage II–III, while raising concerns requiring clarification, including inaccurate subgroup patient counts, replicated or misattributed HORG data, and erroneous figure inclusion of other studies. The authors report updated pooled results showing no significant OS differences for 3- vs 6-month regimens in stage III.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/considerations-regarding-an-updated-meta-analysis-of-the-optimal-duration-of-oxaliplatin-based-adjuvant-chemotherapy/336468/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/considerations-regarding-an-updated-meta-analysis-of-the-optimal-duration-of-oxaliplatin-based-adjuvant-chemotherapy/336468.png","ImageObject",300,407,{"name":42,"@type":43},"Noah","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What treatment durations does the cited meta-analysis recommend for specific colon cancer risk groups?","Question",{"text":63,"@type":64},"It recommends exclusively a 6-month FOLFOX regimen for high-risk stage III colon cancer and suggests a 3-month CAPEOX regimen for stage II–III colon cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What concern is raised regarding the reported DFS subgroup results?",{"text":68,"@type":64},"The letter notes an inaccurate representation of the total enrolled patient numbers in subgroup analyses, which could mislead readers about the sample size behind those results.",{"name":70,"@type":61,"acceptedAnswer":71},"How does the letter address issues found in the figures related to included studies and OS results?",{"text":72,"@type":64},"It states that HORG data were replicated incorrectly, that Figure 5 includes data from studies not matching the intended stage, and that additional eligible studies (e.g., Yoshino et al.) should be included. After correction, it reports no statistically significant OS differences between 3- and 6-month regimens for stage III.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336468,1790164201,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":26,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":97,"preview_page_count":26,"preview_urls":144},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","’Correspondence  \nConsiderations regarding an updated meta-analysis of the optimal duration ofoxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer  \nHuayang Pang, PhDa,b , Menghua Yan, MMa , Lihui Chen, PhDa , Zhou Zhao, PhDa,b , Wei Li, MMa,* , Shouru Zhang, PhDa,* , Hao Sun, PhDa,*  \nDear Editor,  \nWe have read the recent study by Kuang et al. [1] with great interest. This meta-analysis, which includes six large-scale randomized controlled trials involving 10 332 patients, provides compelling evidence that the 6-month FOLFOX regimen should be exclusively recommended for high-risk stage III colon cancer. Moreover, a 3-month CAPEOX regimen is suggested for stage II– III colon cancer. The authors deserve recognition for offering updated evidence to address the contentious aspects of the 2023 NCCN guidelines. However, there are several concerns that necessitate further clariﬁcation.  \nFirstly, when describing the impact of CAPEOX and FOLFOX on disease-free survival (DFS) in patients with stage II–III colon cancer presenting different risk factors, we observed an inaccurate representation of the total number of patients from the enrolled studies (e.g. 1629 patients in the high-risk II stage subgroup, 3301 patients in the low-risk III stage subgroup, and 4416 patients in the high-risk III stage subgroup) . This could potentially mislead readers into believing that these subgroup analyses were based on substantial sample sizes. Therefore, we strongly recommend that the authors provide detailed patient numbers for each subgroup analysis.  \nSecondly, in Figure 3[1], we observed that the HORG[2] data (HR = 1.29 [1.08–1.54]) were replicated in both the overall stage II/III group and the high-risk stage III subgroup. However, upon meticulous examination of the primary literature, it is regrettable  \naDepartment of Gastrointestinal Cancer Center, Chongqing University Cancer Hospital and bChongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, People ’s Republic of China  \nHuayang Pang and Menghua Yan share co-ﬁrst authorship.  \nSponsorships or competing interests that maybe relevant to content are disclosed atthe end of this article.  \n*Corresponding author. Address: Department of Gastrointestinal Cancer Center, Chongqing University Cancer Hospital, Chongqing 400030, People’s Republic of China. Tel.: +86 135 083 704 38. E-mail: [lwaq3356@sina.com](lwaq3356@sina.com) (W. Li), [E-mail: zsrhjp@126.com](E-mail: zsrhjp@126.com) (S. Zhang), [and E-mail: sunhao68@sina.com](and E-mail: sunhao68@sina.com) (H. Sun).  \nCopyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution-ShareAlike License 4.0, which allows others to remix, tweak, and build upon the work, even for commercial purposes, as long as the author is credited and the new creations are licensed under the identical terms.  \nInternational Journal of Surgery (2024) 110:4431–4432  \nReceived 26 February 2024; Accepted 3 March 2024  \nPublished online 25 March 2024  \n[http://dx.doi.org/10.1097/JS9.0000000000001350](http://dx.doi.org/10.1097/JS9.0000000000001350)  \nto note that no data regarding high-risk stage III patients was provided by the HORG trial[2] . After excluding this incorrect data, we found that high-risk stage III patients who underwent a 6-month FOLFOX still exhibited superior DFS compared to those who received a 3-month FOLFOX (HR = 1.37 [1 .11–1.69]; I2 = 2%; Fig. 1A) .  \nThirdly, Figure 5[1] erroneously incorporates the data from Kim et al. [3], where the included data pertains to stage II/III rather than stage III colon cancer. Furthermore, it is essential to include another study by Yoshino et al. [4] that meets the inclusion criteria. The reanalyzed pooled outcome reveals no statistically signiﬁcant difference in overall survi","cbCaiep5TniG08hC","https://ap.wps.com/l/cbCaiep5TniG08hC","pdf",328080,"English","# Concerns about the updated meta-analysis\n## Disease-free survival (DFS) subgroup patient counts\n## HORG data handling and reanalysis\n## Figure errors and study inclusion criteria\n## Overall survival (OS) comparisons for 3- vs 6-month regimens\n## Ethical approval, funding, and author information","[{\"question\":\"What treatment durations does the cited meta-analysis recommend for specific colon cancer risk groups?\",\"answer\":\"It recommends exclusively a 6-month FOLFOX regimen for high-risk stage III colon cancer and suggests a 3-month CAPEOX regimen for stage II–III colon cancer.\"},{\"question\":\"What concern is raised regarding the reported DFS subgroup results?\",\"answer\":\"The letter notes an inaccurate representation of the total enrolled patient numbers in subgroup analyses, which could mislead readers about the sample size behind those results.\"},{\"question\":\"How does the letter address issues found in the figures related to included studies and OS results?\",\"answer\":\"It states that HORG data were replicated incorrectly, that Figure 5 includes data from studies not matching the intended stage, and that additional eligible studies (e.g., Yoshino et al.) should be included. After correction, it reports no statistically significant OS differences between 3- and 6-month regimens for stage III.\"}]","Considerations regarding an updated meta-analysis of the optimal duration ofoxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer | PDF",1790015170,[145,149],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/751b683a5429042c202cfbf1c5ea0194.webp",983,1310,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53dea7ce1a840b51ca46d50d468e5c58.webp",982,1309]